These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 19947303)

  • 1. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
    Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
    Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
    Gross B
    J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide in type 2 diabetes mellitus.
    Baruah MP; Chaudhury T; Sethi BK; Dharmalingam M
    J Indian Med Assoc; 2012 May; 110(5):335-8. PubMed ID: 23360033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
    Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide: a review of its use in type 2 diabetes mellitus.
    Croom KF; McCormack PL
    Drugs; 2009 Oct; 69(14):1985-2004. PubMed ID: 19747013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?
    Besemer F; Verschoor AJ; Diamant M; Hoogma RP
    J Diabetes Complications; 2012; 26(5):458-9. PubMed ID: 22727533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinedione derivatives in type 2 diabetes mellitus.
    Tack CJ; Smits P
    Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.